1 / 106

Treatment of Diffuse Large B-Cell Lymphoma M. Pfreundschuh German High Grade Non-Hodgkin´s Lymphoma Study Group (DSHNH

Treatment of Diffuse Large B-Cell Lymphoma M. Pfreundschuh German High Grade Non-Hodgkin´s Lymphoma Study Group (DSHNHL) Med. Klinik I, Saarland University Medical School Homburg / Saar, Germany. DSHNHL 09-19-00. Update on Clinical Trials . Groups contacted: Australia ALLG +

Angelica
Télécharger la présentation

Treatment of Diffuse Large B-Cell Lymphoma M. Pfreundschuh German High Grade Non-Hodgkin´s Lymphoma Study Group (DSHNH

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Treatment of Diffuse Large B-Cell Lymphoma M. Pfreundschuh German High Grade Non-Hodgkin´s Lymphoma Study Group (DSHNHL) Med. Klinik I, Saarland University Medical SchoolHomburg / Saar, Germany DSHNHL 09-19-00

  2. Update on Clinical Trials Groups contacted: Australia ALLG + France Gela + Europe EORTC + Germany DSHNHL + Netherlands HOVON + Scandinavia Nordic Group + Spain GEATANO + United Kigdom NCRI + USA CALGB + ECOG + SWOG +

  3. Current Randomized Trials IPI=0 No bulk IPI=0 Elderly aaIPI=0 Elderly 0/I U N F I T I,noBulk Limited Limited Elderly Bulk and /or IPI=1 IPI=1 Elderly II-IV Elderly IPI=1,2,3 Elderly II-IV aaIPI=2,3 aaIPI=2,3 aaIPI=2,3 U S A (SWOG) Germany France (GELA) U N F I T Ov er 70 U S A (CALBG) U K (NCRI) Japan (JCOG) DSHNHL09/2000

  4. CALGB:50303 Phase III Randomized Study of R-CHOP v. DA-EPOCH-R with Microarray Treatment completed ARM A: R-CHOP C3 C4 C6 C1 C7 C2 C8 C5 Tumor Biopsy Blood Samples Randomization Stage Stage Stage C3 C4 C6 C1 C7 C2 C8 C5 ARM B: DA-EPOCH-R Treatment completed if no change C5 to C7 staging Treatment completed if change C5 to C7 staging Repeat Blood Samples at Staging Proteomics/Pharmacogenomics 6 9 15 0 18 3 21 25 12 Time Line (weeks)

  5. NCRI trial: R-CHOP 14 vs 21 RANDOMISATION R-CHOP 21 CHOP 21  8 cycles Rituximab  8 cycles N=540 Eligible patients Stratified by IPI (0 or 1 vs. 2 vs. 3 vs. 4 or 5) Age <60 vs. 60 Treatment centre R-CHOP 14 CHOP 14  6 cycles Rituximab  8 cycles N=540

  6. Current Randomized Trials IPI=0 No bulk IPI=0 Elderly aaIPI=0 Elderly 0/I U N F I T I,noBulk Stage I Non-Bulk Limited Limited Elderly Bulk and /or IPI=1 IPI=1 Elderly II-IV Elderly IPI=1,2,3 Elderly II-IV aaIPI=2,3 aaIPI=2,3 aaIPI=2,3 U S A (SWOG) Germany France (GELA) U N F I T Ov er 70 U S A (CALBG) U K (NCRI) Japan (JCOG) DSHNHL09/2000

  7. Trial Design 6 x CHOP-like + 30–40 Gy (Bulk, E) CD20+ DLBCL 18–60 years IPI 0,1 Stages II-IV, I with bulk Random. 6 x CHOP-like + rituximab + 30–40 Gy (Bulk, E)

  8. Time to Treatment Failure 1.0 median observation time: 34 months 0.9 0.8 0.7 59% 0.6 Probability 0.5 0.4 CHEMO (n=410) 0.3 0.2 0.1 0.0 0 10 20 30 40 50 60 M o n t h s Pfreundschuh et al., Lancet Oncology 2006

  9. Time to Treatment Failure 1.0 0.9 79% 0.8 R-CHEMO (n=413) 0.7 59% 0.6 p = 0.000 000 02 Probability 0.5 0.4 CHEMO (n=410) 0.3 0.2 0.1 0.0 0 10 20 30 40 50 60 M o n t h s Pfreundschuh et al., Lancet Oncology 2006

  10. Overall Survival

  11. Overall Survival 1.0 0.9 84% 0.8 CHEMO (n=410) 0.7 0.6 Probability 0.5 0.4 0.3 0.2 0.1 0.0 0 10 20 30 40 50 60 M o n t h s Pfreundschuh et al., Lancet Oncology 2006

  12. Overall Survival 93% 1.0 R-CHEMO (n=413) 0.9 p = 0.0001 84% 0.8 CHEMO (n=410) 0.7 0.6 Probability 0.5 0.4 0.3 0.2 0.1 0.0 0 10 20 30 40 50 60 M o n t h s Pfreundschuh et al., Lancet Oncology 2006

  13. Progress in the treatment of Young good-prognosis DLBCL R-CHO(E)P (2004) CHOEP (2001-2003) CHOP-21 (1975-2001) % Surviving 40 20 0 0 1 2 3 4 M O N T H S

  14. Progress in the treatment of Young good-prognosis DLBCL R-CHOP (2005) CHOEP (2001-2003) CHOP-21 (1975-2001) % Surviving 40 20 0 0 1 2 3 4 M O N T H S

  15. Current Randomized Trials IPI=0 No bulk IPI=0 Elderly aaIPI=0 Elderly 0/I U N F I T I,noBulk Stage I Non-Bulk Limited Limited Elderly Bulk and /or IPI=1 IPI=1 Elderly II-IV Elderly IPI=1,2,3 Elderly II-IV aaIPI=2,3 aaIPI=2,3 aaIPI=2,3 U S A (SWOG) Germany France (GELA) U N F I T Ov er 70 U S A (CALBG) U K (NCRI) Japan (JCOG) DSHNHL09/2000

  16. SWOG Approach for „Limited Stage“ C H O P C H O P C H O P SWOG    24 12 An alternative for good-prognosis?

  17. SWOG Approach for „Limited Stage“ C H O P C H O P C H O P SWOG    24 12 An alternative for good-prognosis?  encouraging (short-term) results  published in abstract form only  small number of patients (62)  uncommon population - >60 years, stage I / non-bulk - <60 years: stage I / bulky (or LDH or ECOG >1) - <60 years: stage II / non-bolky („very favorable“)

  18. SWOG Approach for „Limited Stage“ C H O P C H O P C H O P SWOG    24 12 An alternative for good-prognosis?  encouraging (short-term) results  published in abstract form only  small number of patients (62)  uncommon population - >60 years, stage I / non-bulk - <60 years: stage I / bulky (or LDH or ECOG >1) - <60 years: stage II / non-bolky („very favorable“)

  19. SWOG Approach for „Limited Stage“ C H O P C H O P C H O P SWOG    24 12 An alternative for good-prognosis?  encouraging (short-term) results  published in abstract form only  small number of patients (62)  uncommon population - >60 years, stage I / non-bulk - <60 years: stage I / bulky (or LDH or ECOG >1) - <60 years: stage II / non-bolky („very favorable“)

  20. SWOG Approach for „Limited Stage“ C H O P C H O P C H O P SWOG    24 12 An alternative for good-prognosis?  encouraging (short-term) results  published in abstract form only  small number of patients (62)  uncommon population - >60 years, stage I / non-bulk - <60 years: stage I / bulky (or LDH or ECOG >1) - <60 years: stage II / non-bolky („very favorable“)

  21. Current Randomized Trials IPI=0 Elderly 0/I Elderly aaIPI=0 U N F I T IPI=1 Elderly IPI=1,2,3 Elderly II-IV aaIPI=2,3 France (GELA) DSHNHL09/2000

  22. MTX MTX IFM - VP16 IFM - VP16 ARA-C ARA-C ACVBP 14 0 2 4 8 12 22 Wks R No CNS prophylaxis 0 2 4 8 12 22 Wks R-ACVBP 14 LNH 03-1B<65 years, aaIPI = 0N. Ketterer, F Reyes Primary endpoint: EFS Expected improvement: 10% at 2 years with R-ACVBP (83 to 93%) 400 patients required (in 4 years)

  23. Current Randomized Trials IPI=0 Elderly 0/I Elderly aaIPI=0 U N F I T IPI=0 No bulk IPI=1 Elderly Bulky disease and /or IPI=1 Elderly IPI=1,2,3 Elderly II-IV aaIPI=2,3 aaIPI=2,3 France (GELA) Germany DSHNHL09/2000

  24. Cox Regression Analysis* Parameter Hazard Ratio (95%-CI) Significance Treatment arm 0.4 p=0.000000003 (0.3;0.6) Bulky disease 1.7 p=0.0003 (1.3;2.2) IPI 1.6 p=0.0008 (1.2;2.2) * for primary endpoint TTF

  25. 1.0 0.9 0.8 0.7 0.6 Probability 0.5 0.4 0.3 0.2 0.1 0.0 0 10 20 30 40 50 60 Months C H E M O: T T F R-C H E M O: T T F very favorable 89% 1.0 0.9 0.8 0.7 76% 0.6 Probability less favorable 0.5 0.4 0.3 0.2 0.1 0.0 0 10 20 30 40 50 60 Months CHEMO R-CHEMO p IPI = 0 and no Bulk (n=108/101) 78% 89% 0.054 IPI = 0 and Bulk (n=70/73) 61% 78% 0.064 IPI = 1 and no Bulk (n=105/107) 57% 76% 0.034 IPI = 1 and Bulk (n=127/132) 44% 74% 0.0000003

  26. TTF of Prognostic Subgroups Very Favorable (IPI=0, no bulk) Less Favorable (IPI=1 and/or bulk) R-CHOP 97% 1.0 1.0 R-CHOP 78% 0.9 0.9 0.8 87% R-CHOEP 0.8 0.7 76% R-CHOEP 0.7 0.6 Probability 0.6 Probability 0.5 0.5 0.4 0.4 0.3 0.3 p = 0.637 0.2 0.2 p = 0.142 0.1 0.1 0.0 0.0 0 10 20 30 40 50 60 0 10 20 30 40 50 60 Months Months Pfreundschuh et al., Lancet Oncology 2006

  27. 93% R-CHOEP (n=130) 1.0 0.9 90% R-CHOP (n=160) 0.8 0.7 0.6 0.5 0.4 0.3 0.2 p = 0.891 0.1 0.0 0 10 20 30 40 50 60 Months Overall Survival Very Favorable (IPI=0, no bulk) Less Favorable (IPI=1 and/or bulk) R-CHOP (n=39) 100% 1.0 0.9 R-CHOEP (n=51) 96% 0.8 0.7 0.6 Probability Probability 0.5 0.4 0.3 0.2 p = 0.173 0.1 0.0 0 10 20 30 40 50 60 Months Pfreundschuh et al., Lancet Oncology 2006

  28. Current Randomized Trials IPI=0 Elderly 0/I Elderly aaIPI=0 U N F I T IPI=0 No bulk IPI=1 Elderly Bulky disease and /or IPI=1 Elderly IPI=1,2,3 Elderly II-IV aaIPI=2,3 aaIPI=2,3 France (GELA) Germany DSHNHL09/2000

  29. Current Randomized Trials IPI=0 Elderly aaIPI=0 Elderly 0/I U N F I T Cure95% IPI=0 No bulk Cure100% IPI=1 Elderly Bulky disease and /or IPI=1 Elderly IPI=1,2,3 Elderly II-IV aaIPI=2,3 aaIPI=2,3 France (GELA) Germany DSHNHL09/2000

  30. FLYER (6-6/6-4) STUDY DESIGN C H O P C H O P C H O P C H O P C H O P C H O P R R R R R R Stage I/II aaIPI=0 No Bulk 18-60 years R d 1 d 64 d 106 C H O P C H O P C H O P C H O P R R R R R R

  31. Current Randomized Trials IPI=0 Elderly aaIPI=0 U N F I T IPI=0 No bulk IPI=1 Elderly Bulky disease and /or IPI=1 Elderly IPI=1,2,3 aaIPI=2,3 aaIPI=2,3 France (GELA) Germany DSHNHL09/2000

  32. Current Randomized Trials IPI=0 Elderly aaIPI=0 U N F I T IPI=0 No bulk IPI=1 Elderly Cure90% Bulky disease and /or IPI=1 Elderly IPI=1,2,3 Cure90% aaIPI=2,3 aaIPI=2,3 France (GELA) Germany DSHNHL09/2000

  33. 0 2 4 6 10 14 24 Wks LNH 03-2B<60 years, aaIPI = 1C. Recher, H. Tilly MTX IFM - VP16 ARA-C R-ACVBP 14 R 4 IT MTX 0 3 6 9 12 15 18 21 Wks R-CHOP 21 Primary endpoint: EFS Expected improvement: 10% at 2 years with R-ACVBP (75 to 85%) 380 patients required (in 4 years)

  34. Current Randomized Trials IPI=0 Elderly aaIPI=0 U N F I T IPI=0 No bulk IPI=1 Elderly Cure90% Bulky disease and /or IPI=1 Elderly IPI=1,2,3 Cure90% aaIPI=2,3 aaIPI=2,3 France (GELA) Germany DSHNHL09/2000

  35. Treatment for IPI=1 and/or „Bulk“ UNFOLDER (21/14) STUDY DESIGN C H O P 21 C H O P 21 C H O P 21 C H O P 21 C H O P 21 C H O P 21 + / - Radiatio Bulk / E Rando R R R R R R d 1 d 1 d 75 d 105 C H O P 14 C H O P 14 C H O P 14 C H O P 14 C H O P 14 C H O P 14 + / - Radiatio Bulk / E R R R R R R

  36. Current Randomized Trials IPI=0 No bulk IPI=0 Elderly aaIPI=0 U N F I T Stage I Non-Bulk I,noBulk Limited Limited Elderly Bulk and /or IPI=1 IPI=1 Elderly II-IV Elderly aaIPI 1,2,3 aaIPI=2,3 aaIPI=2,3 aaIPI=2,3 U S A (SWOG) Germany France (GELA) U N F I T Ov er 70 U S A (CALBG) U K (NCRI) Japan (JCOG) DSHNHL09/2000

  37. Current Randomized Trials IPI=0 No bulk IPI=0 Elderly IPI=0 U N F I T Stage I Non-Bulk I,noBulk Limited Limited Limited Elderly Bulk and /or IPI=1 IPI=1 Elderly II-IV Elderly aaIPI 1,2,3 Cure 60% Cure 60% Cure 60% U S A (SWOG) Germany France (GELA) U N F I T Ov er 70 U S A (CALBG) U K (NCRI) DSHNHL09/2000

  38. HD-Chemotherapy in Primary Aggressive NHL A „foggy“ situation ….

  39. HD-Chemotherapy in Primary Aggressive NHL Author Population Rando EFS OS Haioun et al., 1994 1 RF, Bulk CR n.s. n.s. 2000  2 RF CR 0.02* 0.04* Verdonck et al., 1994 II-IV <CR n.s. n.s. Gianni et al., 1997 I/IIbulky,III/IV all 0.004 n.s. Santini et al., 1998 IIbulky,III/IV all n.s. n.s. 2 RF* 0.008* n.s. Kluin-N. et al., 2001 all CR n.s. n.s. Kaiser et al., 2002 LDH >UNV CR, PR n.s. n.s. Gisselbrecht et al., 2002 RF all -0.01 -0.009 Martelli et al., 2003 2 RF CR, PR n.s. n.s. Sertoli et al., 2003 IIbulky,III/IV all n.s. n.s. MISTRAL 2005 IPI >2RD all n.s. n.s. Milpied et al., 2004 <3RF all 0.03 n.s * retrospective subset analysis

  40. HD-Chemotherapy in Primary Aggressive NHL Verdonck et al., 1994 Gianni et al., 1997 Santini et al., 1998 Haioun et al., 1996 / 2000 Kluin-N. et al., 2001 Kaiser et al., 2002 Gisselbrecht et al., 2002 Martelli et al., 2003 Sertoli et al., 2003 Milpied et al., 2002 ?

  41. HD-Chemotherapy in Primary Aggressive NHL Author Population Rando EFS OS Haioun et al., 1994 1 RF, Bulk CR n.s. n.s. 2000  2 RF CR 0.02* 0.04* Verdonck et al., 1994 II-IV <CR n.s. n.s. Gianni et al., 1997 I/IIbulky,III/IV all 0.004 n.s. Santini et al., 1998 IIbulky,III/IV all n.s. n.s. 2 RF* 0.008* n.s. Kluin-N. et al., 2001 all CR n.s. n.s. Kaiser et al., 2002 LDH >UNV CR, PR n.s. n.s. Gisselbrecht et al., 2002 RF all -0.01 -0.009 Martelli et al., 2003 2 RF CR, PR n.s. n.s. Sertoli et al., 2003 IIbulky,III/IV all n.s. n.s. Milpied et al., 2004 <3RF all 0.03 n.s * retrospective subset analysis

  42. The NEW ENGLAND JOURNAL of MEDICINE: A misleading title …

  43. GOELAMS Trial CHOP vs. High-Dose in Young IPI=2,3

  44. GOELAMS Trial Design Suggestive Time S c a l e

  45. GOELAMS Trial Design R e a l t i m e s c a l e C H O P 21 C H O P 21 C H O P 21 C H O P 21 C H O P 21 C H O P 21 C H O P 21 C H O P 21 Rando days 0 20 40 60 80 100 120 140 d 99 B EAM HD-MTX + AraC C E E P 15 C E E P 15

  46. YOUNG HIGH-RISK PATIENTS:SUMMARY/PERSPECTIVES • CHOP-21 = formal standard • CHOP-21 = hard to justify • Conventional high-dose debated • Novel approaches needed

  47. Therapeutic Groups Young Poor-Prognosis • DSHNHL: Mega-CHOEP III • IIL: DLCL-04 III • SWOG: S9704 III • Roma-Bologna II • G E L A: LNH 03-3B II • Nordic Group: LBC-04 II DSHNHL09/2000

  48. DSHNHL 2002-1 („Mega-CHOEP“): TRIAL DESIGN (60 YRS., AGE-ADJUSTED IPI )2 PBSC PBSC PBSC n=230 mCHOEP I mCHOEP II mCHOEP III mCHOEP IV CYC 1500 CYC 4500 CYC 4500 CYC 6000 ADR 70 ADR 70 ADR 70 ADR 70 VCR 2 VCR 2 VCR 2 VCR 2 ETO 600 ETO 960 ETO 960 ETO 1480 PRD 500 PRD 500 PRD 500 PRD 500 1 22 43 64 77 98 days R CHOEP-14 CHOEP-14 CHOEP-14 CHOEP-14 CHOEP-14 CHOEP-14 CHOEP-14 CHOEP-14 n=230 CHOEP-14: CYC 750 VCR 2 ADR 50 PRED 500 ETO 300 G-CSF = rando: + / - Rituximab

  49. DSHNHL 2002-1 („Mega-CHOEP“): TRIAL DESIGN (60 YRS., AGE-ADJUSTED IPI )2 PBSC PBSC PBSC n=230 mCHOEP I mCHOEP II mCHOEP III mCHOEP IV CYC 1500 CYC 4500 CYC 4500 CYC 6000 ADR 70 ADR 70 ADR 70 ADR 70 VCR 2 VCR 2 VCR 2 VCR 2 ETO 600 ETO 960 ETO 960 ETO 1480 PRD 500 PRD 500 PRD 500 PRD 500 1 22 43 64 77 98 days R CHOEP-14 CHOEP-14 CHOEP-14 CHOEP-14 CHOEP-14 CHOEP-14 CHOEP-14 CHOEP-14 n=230 CHOEP-14: CYC 750 VCR 2 ADR 50 PRED 500 ETO 300 G-CSF = rando: + / - Rituximab

  50. 1.0 observation time19 months 1.0 observation time55 months .9 .9 .8 .8 .7 .7 .6 .6 .5 .5 .4 .4 .3 .3 TTF (1y): 73.5% .2 .2 TTF (2y) : 75.0% .1 .1 0.0 0.0 0 5 10 15 20 25 30 0 10 20 30 40 50 60 70 80 Mega-CHOEP Phase II Trials TTF without and with Rituximab R-Mega-CHOEP (n=124) Mega-CHOEP (n=92)

More Related